US FDA Approved Lecanemab Medicine to Treat Alzheimer’s Disease
A new medication that aims to slow Alzheimer’s disease patients’ cognitive decline was approved by the US Food and Drug Administration (FDA). An expedited approval process was used to approve the new treatment, Leqembi or lecanemab. It comes after the FDA approved Aduhelm, an anti-Alzheimer’s medication that was criticized by a congressional investigation for alleged […]
Continue Reading